Attached files
Exhibit 23.1
Consent of Independent Registered Public Accounting
Firm
We
hereby consent to the incorporation by reference in the
Registration Statements on Form S-8 (Nos. 333-167175,
333-196464, 333-210182, 333-224120, and 333-233571), Form S-3 (Nos.
333-224951, 333-248201), and Form S-1 (No. 333-228212) of our
report dated March 31, 2021 included in this Annual Report on Form
10-K of Tenax Therapeutics, Inc. and Subsidiary (the
“Company”), relating to the consolidated balance sheets
of the Company as of December 31, 2020 and 2019, and the related
consolidated statements of operations and comprehensive loss,
stockholders’ equity, and cash flows, and the related notes
(which report expresses an unqualified opinion and contains an
explanatory paragraph regarding substantial doubt about the
Company’s ability to continue as a going concern) for each of
the years in the two-year period ended December 31,
2020.
/s/ CHERRY BEKAERT LLP
Raleigh,
North Carolina
March
31, 2021